All News #Library
Biotech
Actinogen Starts Open-Label Phase For Xanamia Alzheimer`s Trial
01 Apr 2026 //
GLOBENEWSWIRE
Actinogen secures FDA Agreement to Advance Xanamem for Alzheimer
15 Sep 2025 //
GLOBENEWSWIRE
Actinogen Confirms 100th Participant in XanamIA Alzheimer`s Trial
30 Jun 2025 //
PR NEWSWIRE
Australian biotech`s cortisol blocker fails to improve in ph 2 depression
12 Aug 2024 //
FIERCE BIOTECH
Australian Biotech`s Cortisol Blocker Fails In Phase 2 Depression Study
12 Aug 2024 //
FIERCE BIOTECH

Market Place
Sourcing Support